PTX3 and acute myeloid leukemia: In an ongoing prospective, randomized, stratified, double-blind clinical trial patients with acute myelogenous leukemia receiving intensive chemotherapy are stratified based on the underlying PTX3 SNPs, as high- and low-risk for IMI, and subsequently randomized to either posaconazole or fluconazole (1:1 and 1:3 for the high- and low-risk patients, respectively) [35].